MedTrace Logo

Investigations of the Pathophysiology of Gilles de la Tourette Syndrome. Part 2: 7T MRI

NCT05233306 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 65

Last updated 2024-03-29

No results posted yet for this study

Summary

Gilles de la Tourette syndrome (GTS; also known as Tourette syndrome) is a congenital neuropsychiatric disorder. Characteristic symptoms are so-called tics-rapid, repetitive movements (motor tics) or vocalizations (vocal tics) that start suddenly without any apparent purpose. Previous research supports the hypothesis of defective regulation (dysregulation) of the dopaminergic system, with particular discussion of dysfunction of tonic/phasic dopamine release or dopaminergic hyperinnervation. Moreover, given the complex interaction of different neurotransmitters, especially in the basal ganglia, it can be assumed that abnormal dopaminergic transmission also affects other transmitter systems, such as glutamate (Glu) or γ-aminobutyrate (GABA). Furthermore, recent results suggest an abnormality in cerebral iron metabolism in GTS. Since iron is accumulated in dopamine vesicles and plays a central role in dopamine synthesis, this observation may also be related to dysfunction of the dopaminergic system. Therefore, in this multimodal study, the investigators aim to combine positron emission tomography (PET), magnetic resonance imaging (MRI), and magnetic resonance spectroscopy (MRS) methods comparing patients with GTS and a control cohort.

In Part 2 of this study, MRI and MRS at 7 Tesla are employed to investigate (i) the concentrations of Glu, glutamine and GABA in the corpus striatum and the cortex cingularis anterior and (ii) the subcortical iron concentration.

Conditions

  • Gilles de la Tourette Syndrome
  • Tourette Syndrome

Interventions

DEVICE

MRI scanner (7 Tesla)

MRI and MRS examination at 7 Tesla; protocol duration of approx. 75 min

Sponsors & Collaborators

  • Hannover Medical School

    collaborator OTHER

  • Leipzig University Medical Center

    collaborator OTHER

  • Max Planck Institute for Human Cognitive and Brain Sciences

    lead OTHER

Principal Investigators

  • Harald E Möller, PhD · Max Planck Institute for Human Cognitive and Brain Sciences

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-01-27
Primary Completion
2023-04-06
Completion
2023-07-07

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05233306 on ClinicalTrials.gov